The drug major on Wednesday announced its partnership with the Premier Medical Corporation for commercialisation of the rapid antigen test kits for Covid-19 in India from this week.In this collaboration, Cipla will be responsible for the marketing and distribution of the rapid antigen detection test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation.
The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient s body, generating results within 15-20 minutes. Only authorised labs are permitted by ICMR to conduct the rapid antigen testing. The test will be marketed under the brand name CIPtest .
The benchmark indices traded in a narrow range in mid-morning trade. Metal shares advanced for the fifth day in a row. At 11:25 IST, the barometer index, the S&P BSE Sensex, was up 255.41 points or 0.55% to 46,518.58. The Nifty 50 index added 69.65 points or 0.51% at 13,637.50.
A possible approval of Moderna Inc s COVID-19 vaccine this week and progress in US stimulus talks lifted sentiment. The US Federal Reserve will issue an updated policy statement along with new economic projections on Wednesday. Traders will be watching closely for any changes to Fed view on when its benchmark policy rate might rise off zero.
In the broader market, the S&P BSE Mid-Cap index gained 0.80% while the S&P BSE Small-Cap index rose 0.89%. Both these indices outperformed the Sensex.
Cipla announced its partnership with the Premier Medical Corporation
for commercialisation of the rapid antigen test kits for COVID-19 in
India. The company will commence supply from this week.
This is Cipla s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG
ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and
distribution of the Rapid Antigen Detection Test for the qualitative detection of
SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation.
The test is a rapid point-of-care nasopharyngeal swab test that directly detects the
presence or absence of coronavirus antigen in the patient s body, generating results
Telangana gears up to vaccinate 80 lakh people in first phase
Telangana is in the process of creating the required infrastructure for administering Covid-19 vaccine doses to about 80 lakh people in the first phase, once the preventive medicine is available for the state, PTI quoted government sources as saying.
“Even if one vaccinator administers 100 people a day, on an average 10,000 vaccinators can vaccinate 80 lakh people in eight or ten days,” a Health department official told PTI.
Vaccination will be done at all government health facilities such as primary health centers, district hospitals and teaching facilities, the official said.
Bharat Biotech’s Covid vaccine produces robust immune response
Nifty, Sensex creeping higher – Wednesday closing report
Moneylife Digital Team / IANS
0
We had mentioned in Tuesday’s closing report that the momentum in Nifty, Sensex was weakening. On Wednesday, the major indices reported gains while Bank Nifty was flat. On the NSE, there were 1,144 advances, 746 declines and 334 unchanged.
The trends of the major indices in the course of Wednesday’s trading are given in the table below:
HG Infra Engineering Company was declared as L-1 bidder by Ircon International for orders of civil works such as earthwork for railway formation, blanketing work, minor and major bridges, ROB, RUBs, FOBs, track-linking, station building and other service buildings, staff quarters.